Ex-GSK Leader Launches ‘Molecular Clamp’ Vaccine Company Vicebio
Will Begin RSV Studies In 2023
Executive Summary
Venture capital firm Medicxi has chosen Emmanuel Hanon to lead the company, hiring two more ex-GSK veterans to create what they hope is a ‘dream team’ in vaccines.